Cargando…
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)
To compare efficacy outcomes for all approved and investigational first-line (1L) treatment regimens for locally advanced or metastatic urothelial carcinoma (la/mUC) with standard of care (SOC), a network meta-analysis (NMA) was conducted. A systematic literature review (SLR) identified phase 2 and...
Autores principales: | Bloudek, Lisa, Wright, Phoebe, McKay, Caroline, Derleth, Christina Louise, Lill, Jennifer Susan, Lenero, Enrique, Hepp, Zsolt, Ramsey, Scott David, Sullivan, Sean D., Devine, Beth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136539/ https://www.ncbi.nlm.nih.gov/pubmed/37185390 http://dx.doi.org/10.3390/curroncol30040277 |
Ejemplares similares
-
Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling
por: Galsky, Matthew D, et al.
Publicado: (2023) -
Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
por: Fontes, Mariane S, et al.
Publicado: (2022) -
Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology
por: Bloudek, Brian, et al.
Publicado: (2022) -
Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis
por: Hepp, Zsolt, et al.
Publicado: (2021) -
Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program
por: Monteiro, Fernando Sabino M., et al.
Publicado: (2021)